Canagliflozin Research Guide

Full name: Canagliflozin (SGLT2 Inhibitor)

An FDA-approved SGLT2 inhibitor for type 2 diabetes that gained longevity attention after the ITP showed it extended male mouse lifespan. Biohackers use it for glucose control, cardiovascular/kidney protection, and its caloric-loss "metabolic offloading" effect.

How Canagliflozin Works

Blocks the sodium-glucose cotransporter 2 in the kidney, causing excess glucose to be excreted in urine. This lowers blood glucose independent of insulin, reduces blood pressure and weight, and produces cardio-renal protective effects.

Dosing Protocol

• Typical dose: 100-300 mg per day
• Frequency: Once daily
• Duration: Ongoing
• Route: Oral tablet

Reported Benefits

• Insulin-independent glucose lowering
• Cardiovascular protection
• Kidney protection
• Blood pressure reduction
• Weight loss
• Longevity signal (ITP data)

Potential Side Effects

• Genital yeast/urinary infections
• Dehydration/dizziness
• Increased urination
• Rare euglycemic DKA
• Electrolyte shifts

Research Citations

1. Canagliflozin extends male mouse lifespan (ITP) (2020) - Increased median male lifespan by ~14% in the NIA Interventions Testing Program.
2. CANVAS cardiovascular outcomes (2017) - Reduced major adverse cardiovascular events and progression of kidney disease in type 2 diabetics.

Related Anti-Aging Compounds

• Epithalon - Full Profile
• NAD+ - Full Profile
• Humanin - Full Profile
• FOXO4-DRI - Full Profile
• SS-31 (Elamipretide) - Full Profile
• GDF-11 - Full Profile

View full Canagliflozin profile with 3D molecule viewer →